Table 3.
HTA appraisal feedback and process transparency in China and four selected countries
| China | Australia23 | Canada18 24 | England19 | France20 | |
|---|---|---|---|---|---|
| Dossier submission released to public | Initial brief submission only | No | No | Yes | No |
| Dossier assessment | |||||
| Notification to manufacturers | Oral report and advice | Commentary from external evaluation entities and committee advice | Draft reports of assessment body (CADTH) | Committee report and comments from consultees and commentators | List of questions concerning the methods |
| Manufacturers’ feedback | Provide written feedback on the brief report if necessary | Return written response, as well as apply for committee hearings | Submit written comments | Provide supplementary material if NICE agrees; respond to comments and attend meetings with NICE | Return written answers |
| Public contents | None | N/A | CADTH reports | Committee and technical report and stakeholder comments, and responses from NICE | Critical analysis (appended to the opinion form) |
| Appraisal | |||||
| Notification to manufacturers | Oral report and advice | Written advice (committee minutes) | All draft recommendations are posted on the CADTH website for stakeholder feedback | Two representatives from the manufacturers (normally 1 with health economics expertise and 1 with medical expertise) can attend first part of appraisal committee meeting discussions | Opinion draft |
| Manufacturers’ feedback | Provide written feedback on the brief report | Applicants who have received a decision to “not recommend” may request a meeting with the chair | Provide feedback on the draft recommendation, and request reconsideration | Representatives can respond to questions from the appraisal committee and comment on any matters of factual accuracy | Respond to written observations or request meeting with president of CEESP |
| Public contents | None | Recommendations and evidence and rationale behind them | Both the draft recommendation and final recommendations | Consultation document plus stakeholder comments and NICE responses, final decision | Appraisal meeting minutes, the final opinion draft |
CEESP=French Economic and Public Health Committee, CADTH=Canadian Agency for Drugs and Technologies in Health, NICE=National Institute for Health and Care Excellence.